An example of this is Australia, where the inclusion of PSMA PET-CT in urological guidelines has culminated in a government rebated PSMA PET-CT scan for men who have histologically confirmed intermediate or high risk PCa or biochemical recurrent PCa [11,12]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.